Eylea (aflibercept) is a proven treatment option for patients with wet age-related macular degeneration.1,2 Results from the recent ALTAIR study demonstrate how a proactive treat and extend regimen with Eylea can facilitate meaningful reductions in injection numbers, allowing clinicians to tailor treatment schedules to suit the individual needs of eligible patients.1,2
Contact: Bayer Account Manager
References
1. Ohji, M. et al. (2020) Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial. Advances in Therapy: [ePub ahead of print] https://doi.org/10.1007/s12325-020-01236-x
2. Eylea Approved Product Information dated Nov 2018. Please review full PI before prescribing: www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI? OpenForm&t=&q=aflibercept. Bayer Australia Ltd. ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073. Date of preparation: March 2020 / PP-M_AFL-AU-0018
